The 7 most recent market catalysts affecting $DVA, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 4, 2026
Corporate Catalyst
Bearish
Impact 65
DaVita Reaches Preliminary Settlement Class Agreement Following Ransomware Attack
DaVita Inc. has reached a preliminary settlement agreement in a class-action lawsuit following a ransomware attack in April 2025 that compromised the personal and health informatio…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 55
DaVita Enters Value-Based Care Agreement With Humana Medicare Advantage To Provide Care To Members With Chronic Kidney Disease Stages 3B–5
DaVita (DVA) has announced an expansion of its value-based care partnership with Humana (HUM) to address chronic kidney disease (CKD) stages 3B-5 for over 10,000 Medicare Advantage…
Aug 5, 2026
Corporate Catalyst
Bearish
Impact 75
DaVita shares are trading lower after the company reported Q2 financial results. The company disclosed a quarter-over-quarter decline in its revenue per treatment.
The decline in DaVita's revenue per treatment is a significant concern as it directly impacts the company's top-line growth and profitability. This metric is crucial for healthcare…
Aug 4, 2026
Corporate Catalyst
Neutral
Impact 55
DaVita Form4 Filing Shows Berkshire Hathaway Sells 182,980 Davita Shares At An Average $199.55/Share, Still Owns About 28.7M Shares
Berkshire Hathaway, a prominent institutional investor, reported selling 182,980 shares of DaVita at an average price of $199.55 per share. While any sale by a major investor like …
Aug 4, 2026
Corporate Catalyst
Bearish
Impact 75
DaVita shares are trading lower after the company reported Q2 financial results. The company disclosed a quarter-over-quarter decline in its revenue per treatment.
The decline in DaVita's revenue per treatment is a significant concern for investors, as it directly impacts the company's top-line growth and profitability. This metric is a key i…
Aug 4, 2026
Corporate Catalyst
Bullish
Impact 92
DaVita Q2 Adj. EPS $4.02 Beats $3.88 Estimate, Sales $3.554B Beat $3.496B Estimate
DaVita's Q2 earnings of $4.02 per share significantly beat the analyst consensus of $3.88, representing a substantial 36.27% increase year-over-year. Similarly, quarterly sales of …
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 55
Truist Securities Maintains Hold on DaVita, Raises Price Target to $250
Truist Securities analyst David Macdonald maintained a 'Hold' rating on DaVita (DVA) but raised the price target from $205 to $250. This action suggests that while the analyst sees…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.